Patients with HER2-positive breast cancer, whose disease has progressed after being treated initially with pertuzumab in combination with trastuzumab and a taxane, can respond well to treatment with T-DM1—a drug that combines ...
Nov 15, 2019
0
2
Guiding chemotherapy to a tumour by attaching it to the antibody-based target drug Herceptin (trastuzumab) is effective at treating women with breast cancer who have no other treatment options, a new clinical trial shows.
Jun 28, 2019
0
4
About one of every five breast cancers presents with high levels of HER2 proteins. Known as HER2-positive breast cancer, these tumors typically show an aggressive behavior—a greater likelihood of metastasis and relapse ...
Jun 25, 2019
0
0
(HealthDay)—Treatment with a combination of alpelisib and fulvestrant prolongs progression-free survival among patients with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative ...
Jun 24, 2019
0
1
A UCLA-led study has found that using a drug called ribociclib in combination with a common hormone therapy may help premenopausal women with the most common type of breast cancer live longer than if they only receive the ...
Jun 3, 2019
0
2
Common and rare SORLA single nucleotide polymorphisms have been associated with the development of Alzheimer's disease. So far, SORLA has been mainly studied in neurons, but the new study focused on SORLA's role in cancer ...
May 28, 2019
0
3
De-escalation approaches in the treatment of women with HER2 positive breast cancer need to be personalised, according to Dr. Carmen Criscitiello, European Institute of Oncology, Milan, Italy. Her comments come on the occasion ...
May 1, 2019
0
3
An international clinical trial, published in Nature Medicine, revealed that combining RNA and DNA profiling gives a far more precise indication of the active biological elements within a tumor, enabling clinicians to more ...
Apr 30, 2019
0
77
Surgery was associated with higher survival rates for patients with HER2-positive (HER2+) stage 4 breast cancer compared with those who did not undergo surgery, according to results presented at the AACR Annual Meeting 2019, ...
Apr 2, 2019
0
0
A study by University of Colorado Cancer Center and Rain Therapeutics, Inc. presented at the American Association for Cancer Research (AACR) Annual Meeting 2019 shows that the clinical-stage drug, tarloxotinib, is active ...
Apr 1, 2019
0
4
